Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Evotec signs research collaboration and licensing deal with Debiopharm Group

Evotec AG announced today a research collaboration and licensing deal with Debiopharm Group™, Lausanne, Switzerland.

2 Apr 2014

FORMA Therapeutics signs second strategic collaboration and option agreement with Celgene

FORMA Therapeutics, an innovative R&D organization in pursuit of ground-breaking medicines in oncology and other therapeutic areas, today announced a second strategic collaboration and option agreement with Celgene Corporation, a leader in addressing high unmet medical needs.

1 Apr 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

Xenon collaborates with Genentech to develop new therapeutic targets for treating pain

Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group, for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain.

26 Mar 2014

IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

IDRI's drug discovery efforts continue to grow with a recently awarded grant extension of $3.4 million from the Bill & Melinda Gates Foundation. The additional funding was awarded to Tanya Parish, Ph.D., IDRI's Vice President of Drug Discovery, and supplements an earlier grant awarded in 2010, for a total of $7.8 million.

25 Mar 2014

New national research consortium focuses on better drug therapies for viral infections

Viral infections with limited or no treatment options can pose a major global health threat, but a new national research consortium centered at the University of Alabama at Birmingham is focused on the discovery of new and better drug therapies as these viruses emerge.

24 Mar 2014

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

20 Mar 2014

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.

20 Mar 2014

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new data from Professor Isabelle Leclercq of Université Catholique de Louvain (Belgium) demonstrating the curative effects of GFT505 in an experimental model of NASH associated with metabolic disorders.

20 Mar 2014

Scientists step in with new way to determine drug safety without using animals

As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety and drug interactions — without using animals.

19 Mar 2014

Daylight Solutions launches world's first laser-based infrared microscopy platform

Daylight Solutions, Inc., a leading manufacturer of molecular detection and imaging solutions in the mid-infrared, today announced the launch of the world's first commercially available laser-based infrared microscopy platform.

From Daylight Solutions Inc 19 Mar 2014

Cellectricon, UCL to host webinar to explore use of primary cells for biomedical research

Cellectricon, a leading provider of advanced cell-based screening technologies and services, will co-host a webinar with top researchers at University College London. The webinar will explore the use of primary cells as a biologically-relevant model for biomedical research, and highlight the new high-throughput techniques and phenotypic screening approaches that are used by UCL to investigate cellular processes in such cells.

From Cellectricon 19 Mar 2014

ChromaTrap™ Chromatin Immunoprecipitation technology receives positive commentary in published paper

Porvair Sciences reports on positive commentary by researchers in published papers citing how using the fast, sensitive ChromaTrap™ Chromatin Immunoprecipitation (ChIP) technology has benefited their research.

From Chromatrap® - Porvair Sciences Ltd 18 Mar 2014

AV drugs could help curb bacteria's growing resistance to antibiotic treatments

A new type of drug could help to combat growing antibiotic resistance, a study finds. Medicines that stop bacteria from harming their hosts, rather than kill them, could prevent bugs from evolving resistance to drug treatments, a review of research in the field suggests.

18 Mar 2014

CRO services division of Galapagos to be acquired by Charles River Laboratories

Charles River Laboratories International, Inc. announced today that it has entered into a definitive agreement to acquire the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus.

13 Mar 2014

Researchers identify new player in onset and progression of heart failure

A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.

13 Mar 2014

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Promethera Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism.

11 Mar 2014

Takeda works with UCL to drive research into tackling muscle disorders

Japanese pharmaceutical company Takeda will work with University College London (UCL) to drive research into tackling muscle disorders, in particular muscular dystrophy.

10 Mar 2014

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Three longtime allies have joined forces to create the new Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence.

7 Mar 2014

Drug Discovery News and Research

Further Reading

Evotec signs research collaboration and licensing deal with Debiopharm Group

FORMA Therapeutics signs second strategic collaboration and option agreement with Celgene

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

Xenon collaborates with Genentech to develop new therapeutic targets for treating pain

IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

New national research consortium focuses on better drug therapies for viral infections

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

Scientists step in with new way to determine drug safety without using animals

Daylight Solutions launches world's first laser-based infrared microscopy platform

Cellectricon, UCL to host webinar to explore use of primary cells for biomedical research

ChromaTrap™ Chromatin Immunoprecipitation technology receives positive commentary in published paper

AV drugs could help curb bacteria's growing resistance to antibiotic treatments

CRO services division of Galapagos to be acquired by Charles River Laboratories

Researchers identify new player in onset and progression of heart failure

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Takeda works with UCL to drive research into tackling muscle disorders

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Fully automated high-throughput screening services for faster drug discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo